UBS Group’s Oncternal Therapeutics ONCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-1,221
Closed -$1.61K – 10775
2024
Q3
$1.61K Buy
1,221
+1,121
+1,121% +$5.41K ﹤0.01% 8595
2024
Q2
$760 Hold
100
– – ﹤0.01% 8781
2024
Q1
$900 Hold
100
– – ﹤0.01% 8314
2023
Q4
$1.07K Sell
100
-579
-85% -$4.17K ﹤0.01% 8410
2023
Q3
$4.08K Buy
679
+178
+36% +$1.25K ﹤0.01% 7477
2023
Q2
$3.46K Buy
501
+298
+147% +$1.96K ﹤0.01% 7627
2023
Q1
$3.18K Sell
203
-35
-15% -$689 ﹤0.01% 8361
2022
Q4
$4.76K Sell
238
-594
-71% -$11.8K ﹤0.01% 9279
2022
Q3
$15K Sell
832
-7,483
-90% -$160K ﹤0.01% 7852
2022
Q2
$184K Buy
8,315
+7,751
+1,374% +$173K ﹤0.01% 4996
2022
Q1
$16K Sell
564
-675
-54% -$24.6K ﹤0.01% 7774
2021
Q4
$56K Sell
1,239
-7,066
-85% -$475K ﹤0.01% 6806
2021
Q3
$692K Buy
8,305
+1,183
+17% +$97.9K ﹤0.01% 4494
2021
Q2
$677K Buy
7,122
+6,958
+4,243% +$826K ﹤0.01% 4503
2021
Q1
$27K Buy
+164
New +$21.7K ﹤0.01% 7111
2020
Q4
– Sell
-193
Closed -$7K – 8898
2020
Q3
$7K Buy
+193
New +$9.46K ﹤0.01% 7156
2020
Q2
– Sell
-5
Closed – – 8482
2020
Q1
$0 Sell
5
-16
-76% -$1.19K ﹤0.01% 8548
2019
Q4
$1K Sell
21
-60
-74% -$6.21K ﹤0.01% 7999
2019
Q3
$8K Sell
81
-11
-12% -$1.13K ﹤0.01% 7300
2019
Q2
$13K Buy
92
+57
+163% +$8.8K ﹤0.01% 6914
2019
Q1
$6K Sell
35
-41
-54% -$6.12K ﹤0.01% 7113
2018
Q4
$8K Buy
76
+27
+55% +$5.4K ﹤0.01% 7371
2018
Q3
$11K Buy
49
+41
+513% +$98.4K ﹤0.01% 7132
2018
Q2
$18K Buy
8
+3
+60% +$7.61K ﹤0.01% 6787
2018
Q1
$11K Sell
5
-4
-44% -$8.91K ﹤0.01% 6824
2017
Q4
$17K Buy
9
+4
+80% +$5.79K ﹤0.01% 6687
2017
Q3
$5K Hold
5
– – ﹤0.01% 7247
2017
Q2
$3K Sell
5
-17
-77% -$10.4K ﹤0.01% 7314
2017
Q1
$15K Buy
22
+1
+5% +$733 ﹤0.01% 6360
2016
Q4
$15K Buy
21
+16
+320% +$17.1K ﹤0.01% 6694
2016
Q3
$5K Hold
5
– – ﹤0.01% 7144
2016
Q2
$4K Hold
5
– – ﹤0.01% 7257
2016
Q1
$3K Sell
5
-1
-17% -$867 ﹤0.01% 7221
2015
Q4
$6K Buy
6
+1
+20% +$1.32K ﹤0.01% 7636
2015
Q3
$5K Hold
5
– – ﹤0.01% 7741
2015
Q2
$9K Sell
5
-13
-72% -$18.5K ﹤0.01% 7558
2015
Q1
$17K Buy
18
+8
+80% +$7.95K ﹤0.01% 7164
2014
Q4
$11K Buy
+10
New +$8.93K ﹤0.01% 8335

Other funds holding ONCT

UBS Group's ONCT Position: Q4 2024 in Review

UBS Group sold out of Oncternal Therapeutics (ONCT) in Q4 2024, closing a stake of 1,221 shares — an estimated $1.61K sold.

UBS Group first reported a position in ONCT in Q4 2014 and held it in 38 quarters. The position peaked at $692K in Q3 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • UBS Group reported no remaining Oncternal Therapeutics position as of Q4 2024 after selling out during the quarter.
  • UBS Group sold 1,221 Oncternal Therapeutics shares in Q4 2024, an estimated $1.61K.
  • UBS Group first reported a position in Oncternal Therapeutics in Q4 2014 and held it in 38 quarters.
  • UBS Group's Oncternal Therapeutics position peaked at $692K in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics as of Q4 2024.

Based on UBS Group's 13F filing for Q4 2024, filed 14 Feb 2025.